Cargando…

Repurposing doxycycline for synucleinopathies: remodelling of α-synuclein oligomers towards non-toxic parallel beta-sheet structured species

Synucleinophaties are progressive neurodegenerative disorders with no cure to date. An attractive strategy to tackle this problem is repurposing already tested safe drugs against novel targets. In this way, doxycycline prevents neurodegeneration in Parkinson models by modulating neuroinflammation. H...

Descripción completa

Detalles Bibliográficos
Autores principales:	González-Lizárraga, Florencia, Socías, Sergio B., Ávila, César L., Torres-Bugeau, Clarisa M., Barbosa, Leandro R. S., Binolfi, Andres, Sepúlveda-Díaz, Julia E., Del-Bel, Elaine, Fernandez, Claudio O., Papy-Garcia, Dulce, Itri, Rosangela, Raisman-Vozari, Rita, Chehín, Rosana N.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5290535/ https://www.ncbi.nlm.nih.gov/pubmed/28155912 http://dx.doi.org/10.1038/srep41755

Ejemplares similares

Rifampicin and Its Derivative Rifampicin Quinone Reduce Microglial Inflammatory Responses and Neurodegeneration Induced In Vitro by α-Synuclein Fibrillary Aggregates
por: Acuña, Leonardo, et al.
Publicado: (2019)

Doxycycline Interferes With Tau Aggregation and Reduces Its Neuronal Toxicity
por: Medina, Luciana, et al.
Publicado: (2021)

CMT-3 targets different α-synuclein aggregates mitigating their toxic and inflammogenic effects
por: González-Lizárraga, Florencia, et al.
Publicado: (2020)

The Chemically-Modified Tetracycline COL-3 and Its Parent Compound Doxycycline Prevent Microglial Inflammatory Responses by Reducing Glucose-Mediated Oxidative Stress
por: Ferreira Junior, Nilson Carlos, et al.
Publicado: (2021)

Rescue of Dopamine Neurons from Iron-Dependent Ferroptosis by Doxycycline and Demeclocycline and Their Non-Antibiotic Derivatives
por: Tourville, Aurore, et al.
Publicado: (2023)

α-Synuclein oligomers and fibrils: partners in crime in synucleinopathies
por: Bigi, Alessandra, et al.
Publicado: (2023)

New Roles of Glycosaminoglycans in α-Synuclein Aggregation in a Cellular Model of Parkinson Disease
por: Lehri-Boufala, Sonia, et al.
Publicado: (2015)

Rifampicin quinone pretreatment improves neuronal survival by modulating microglia inflammation induced by α-synuclein
por: Acuña, Leonardo, et al.
Publicado: (2020)

Doxycycline attenuates l-DOPA-induced dyskinesia through an anti-inflammatory effect in a hemiparkinsonian mouse model
por: dos Santos Pereira, Maurício, et al.
Publicado: (2022)

Dynamic Involvement of Striatal NG2-glia in L-DOPA Induced Dyskinesia in Parkinsonian Rats: Effects of Doxycycline
por: Nascimento, G.C., et al.
Publicado: (2023)

Neuroprotective Effects of a Novel Demeclocycline Derivative Lacking Antibiotic Activity: From a Hit to a Promising Lead Compound
por: Tomas-Grau, Rodrigo, et al.
Publicado: (2022)

α-Synuclein oligomers induce early axonal dysfunction in human iPSC-based models of synucleinopathies
por: Prots, Iryna, et al.
Publicado: (2018)

Low-Expressing Synucleinopathy Mouse Models Based on Oligomer-Forming Mutations and C-Terminal Truncation of α-Synuclein
por: Martinez Hernandez, Ana, et al.
Publicado: (2021)

Glycosaminoglycans from Alzheimer’s disease hippocampus have altered capacities to bind and regulate growth factors activities and to bind tau
por: Huynh, Minh Bao, et al.
Publicado: (2019)

Drug Targeting of α-Synuclein Oligomerization in Synucleinopathies
por: Outeiro, Tiago Fleming, et al.
Publicado: (2008)

Calcium: Alpha-Synuclein Interactions in Alpha-Synucleinopathies
por: Rcom-H'cheo-Gauthier, Alexandre N., et al.
Publicado: (2016)

Metallothionein, Copper and Alpha-Synuclein in Alpha-Synucleinopathies
por: Okita, Yuho, et al.
Publicado: (2017)

Gene Therapy to Modulate Alpha-Synuclein in Synucleinopathies
por: Sandoval, Ivette M., et al.
Publicado: (2021)

Cardiac Alpha-Synuclein Is Present in Alpha-Synucleinopathies
por: Javanshiri, Keivan, et al.
Publicado: (2022)

Effects of oligomer toxicity, fibril toxicity and fibril spreading in synucleinopathies
por: Cascella, Roberta, et al.
Publicado: (2022)

Alpha-Synuclein: Mechanisms of Release and Pathology Progression in Synucleinopathies
por: Brás, Inês C., et al.
Publicado: (2021)

Viral alpha-synuclein knockdown prevents spreading synucleinopathy
por: Menon, Sindhu, et al.
Publicado: (2021)

The Interplay between α-Synuclein and Microglia in α-Synucleinopathies
por: Deyell, Jacob S., et al.
Publicado: (2023)

Propagative α-synuclein seeds as serum biomarkers for synucleinopathies
por: Okuzumi, Ayami, et al.
Publicado: (2023)

Triggering of Inflammasome by Aggregated α–Synuclein, an Inflammatory Response in Synucleinopathies
por: Codolo, Gaia, et al.
Publicado: (2013)

Alpha-Synuclein Targeting Therapeutics for Parkinson's Disease and Related Synucleinopathies
por: Menon, Sindhu, et al.
Publicado: (2022)

Chemical disaggregation of alpha-synuclein fibrils as a therapy for synucleinopathies
por: Wu, Shenjie, et al.
Publicado: (2023)

Biomaterial-Based Nanocomposite for Osteogenic Repurposing of Doxycycline
por: El-Habashy, Salma, et al.
Publicado: (2021)

Drug repurposing screens identify compounds that inhibit α-synuclein oligomers' membrane disruption and block antibody interactions
por: Somavarapu, Arun Kumar, et al.
Publicado: (2023)

Tau Enhances α-Synuclein Aggregation and Toxicity in Cellular Models of Synucleinopathy
por: Badiola, Nahuai, et al.
Publicado: (2011)

Alpha‐synuclein RT‐QuIC in the CSF of patients with alpha‐synucleinopathies
por: Fairfoul, Graham, et al.
Publicado: (2016)

α-Synuclein interacts directly but reversibly with psychosine: implications for α-synucleinopathies
por: Abdelkarim, Hazem, et al.
Publicado: (2018)

Alpha-Synuclein in Skin Nerve Fibers as a Biomarker for Alpha-Synucleinopathies
por: Kim, Jee Young, et al.
Publicado: (2019)

GBA-Associated Synucleinopathies: Prime Candidates for Alpha-Synuclein Targeting Compounds
por: Brockmann, Kathrin
Publicado: (2020)

Beyond the synucleinopathies: alpha synuclein as a driving force in neurodegenerative comorbidities
por: Visanji, Naomi P., et al.
Publicado: (2019)

Lovastatin Alleviates α-Synuclein Aggregation and Phosphorylation in Cellular Models of Synucleinopathy
por: Dai, Lijun, et al.
Publicado: (2021)

Diagnostic value of cerebrospinal fluid alpha-synuclein seed quantification in synucleinopathies
por: Poggiolini, Ilaria, et al.
Publicado: (2021)

α-Synuclein Strains: Does Amyloid Conformation Explain the Heterogeneity of Synucleinopathies?
por: Hoppe, Simon Oliver, et al.
Publicado: (2021)

Lipotoxicity Downstream of α-Synuclein Imbalance: A Relevant Pathomechanism in Synucleinopathies?
por: Tripathi, Arati, et al.
Publicado: (2021)

Pathogenic Impact of α-Synuclein Phosphorylation and Its Kinases in α-Synucleinopathies
por: Kawahata, Ichiro, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_b3p6cuo9rnfsvsklionkah1102